Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: A randomized, double-blind, non-inferiority crossover study

Fabrizio Stocchi, Bonnie P. Hersh, Burton L. Scott, Paul A. Nausieda, Luigi Giorgi, P. Bourgeois, P. P. De Deyn, R. Dom, A. Jeanjean, D. Roubcova, E. Ruzicka, M. Valis, A. Destée, R. Gil, F. Viallet, A. Csanyi, L. Csiba, P. Harcos, J. Czopf, A. TakácsP. Barone, G. Nordera, M. Onofri, W. Drozdowski, H. Kwiecinski, W. Nyka, G. Opala, A. Szczudlik, B. Boothman, D. Burn, B. Castleton, D. Grosset, R. Weiser, C. Bernick, S. Cohen, A. Colcher, N. Leopold, L. Seeberger, N. Stoven

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Objective: This study compares once-daily ropinirole 24-h prolonged release and three-times-daily ropinirole immediate release in patients with early Parkinson's disease. Methods: This multicentre, double-blind, non-inferiority crossover study involved 161 patients randomized to one of four formulation sequences: (1) immediate release-immediate release-prolonged release; (2) immediate release-prolonged release-prolonged release; (3) prolonged release-prolonged release-immediate release; (4) prolonged release-immediate release-immediate release. During a 12-week dose-titration period, ropinirole immediate release was titrated according to the approved labelling; titration of ropinirole 24-h prolonged release started at a higher dose and was more rapid. Patients then entered three consecutive, flexible-dose, 8-week maintenance periods. At the end of the first maintenance period, half of the patients in each formulation group switched to the same or closest dose of the alternative formulation; remaining patients switched at the end of the second maintenance period. Results: At the end of titration, before the first dose switch, there were substantial reductions in mean Unified Parkinson's Disease Rating Scale (UPDRS) motor scores. During maintenance periods, both groups showed similar efficacy on the UPDRS motor score. Overall mean (standard error) change from period baseline was -0.1 (0.28) for ropinirole 24-h prolonged release, and 0.6 (0.30) for ropinirole immediate release (adjusted mean treatment difference -0.7; 95% confidence interval [Ci]: -1.51, 0.10; p= 0.0842). The upper limit of the 95% CI was less than the predefined threshold of 3 points for non-inferiority. Ropinirole 24-h prolonged release was well-tolerated when titrated more rapidly than ropinirole immediate release; overnight switching between formulations was also well-tolerated. Study limitations included complexity of the non-inferiority study design and the forced dose-titration schedule. Conclusion: Ropinirole 24-h prolonged release was effective and well-tolerated in patients with early Parkinson's disease.

Original languageEnglish
Pages (from-to)2883-2895
Number of pages13
JournalCurrent Medical Research and Opinion
Volume24
Issue number10
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Cross-Over Studies
Parkinson Disease
Maintenance
ropinirole
Appointments and Schedules
Confidence Intervals

Keywords

  • Once-daily treatment
  • Parkinson's disease
  • Ropinirole

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease : A randomized, double-blind, non-inferiority crossover study. / Stocchi, Fabrizio; Hersh, Bonnie P.; Scott, Burton L.; Nausieda, Paul A.; Giorgi, Luigi; Bourgeois, P.; De Deyn, P. P.; Dom, R.; Jeanjean, A.; Roubcova, D.; Ruzicka, E.; Valis, M.; Destée, A.; Gil, R.; Viallet, F.; Csanyi, A.; Csiba, L.; Harcos, P.; Czopf, J.; Takács, A.; Barone, P.; Nordera, G.; Onofri, M.; Drozdowski, W.; Kwiecinski, H.; Nyka, W.; Opala, G.; Szczudlik, A.; Boothman, B.; Burn, D.; Castleton, B.; Grosset, D.; Weiser, R.; Bernick, C.; Cohen, S.; Colcher, A.; Leopold, N.; Seeberger, L.; Stoven, N.

In: Current Medical Research and Opinion, Vol. 24, No. 10, 10.2008, p. 2883-2895.

Research output: Contribution to journalArticle

Stocchi, F, Hersh, BP, Scott, BL, Nausieda, PA, Giorgi, L, Bourgeois, P, De Deyn, PP, Dom, R, Jeanjean, A, Roubcova, D, Ruzicka, E, Valis, M, Destée, A, Gil, R, Viallet, F, Csanyi, A, Csiba, L, Harcos, P, Czopf, J, Takács, A, Barone, P, Nordera, G, Onofri, M, Drozdowski, W, Kwiecinski, H, Nyka, W, Opala, G, Szczudlik, A, Boothman, B, Burn, D, Castleton, B, Grosset, D, Weiser, R, Bernick, C, Cohen, S, Colcher, A, Leopold, N, Seeberger, L & Stoven, N 2008, 'Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: A randomized, double-blind, non-inferiority crossover study', Current Medical Research and Opinion, vol. 24, no. 10, pp. 2883-2895. https://doi.org/10.1185/03007990802387130
Stocchi, Fabrizio ; Hersh, Bonnie P. ; Scott, Burton L. ; Nausieda, Paul A. ; Giorgi, Luigi ; Bourgeois, P. ; De Deyn, P. P. ; Dom, R. ; Jeanjean, A. ; Roubcova, D. ; Ruzicka, E. ; Valis, M. ; Destée, A. ; Gil, R. ; Viallet, F. ; Csanyi, A. ; Csiba, L. ; Harcos, P. ; Czopf, J. ; Takács, A. ; Barone, P. ; Nordera, G. ; Onofri, M. ; Drozdowski, W. ; Kwiecinski, H. ; Nyka, W. ; Opala, G. ; Szczudlik, A. ; Boothman, B. ; Burn, D. ; Castleton, B. ; Grosset, D. ; Weiser, R. ; Bernick, C. ; Cohen, S. ; Colcher, A. ; Leopold, N. ; Seeberger, L. ; Stoven, N. / Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease : A randomized, double-blind, non-inferiority crossover study. In: Current Medical Research and Opinion. 2008 ; Vol. 24, No. 10. pp. 2883-2895.
@article{2f89fb3824cb4cc2ae20f7322bfb5c41,
title = "Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: A randomized, double-blind, non-inferiority crossover study",
abstract = "Objective: This study compares once-daily ropinirole 24-h prolonged release and three-times-daily ropinirole immediate release in patients with early Parkinson's disease. Methods: This multicentre, double-blind, non-inferiority crossover study involved 161 patients randomized to one of four formulation sequences: (1) immediate release-immediate release-prolonged release; (2) immediate release-prolonged release-prolonged release; (3) prolonged release-prolonged release-immediate release; (4) prolonged release-immediate release-immediate release. During a 12-week dose-titration period, ropinirole immediate release was titrated according to the approved labelling; titration of ropinirole 24-h prolonged release started at a higher dose and was more rapid. Patients then entered three consecutive, flexible-dose, 8-week maintenance periods. At the end of the first maintenance period, half of the patients in each formulation group switched to the same or closest dose of the alternative formulation; remaining patients switched at the end of the second maintenance period. Results: At the end of titration, before the first dose switch, there were substantial reductions in mean Unified Parkinson's Disease Rating Scale (UPDRS) motor scores. During maintenance periods, both groups showed similar efficacy on the UPDRS motor score. Overall mean (standard error) change from period baseline was -0.1 (0.28) for ropinirole 24-h prolonged release, and 0.6 (0.30) for ropinirole immediate release (adjusted mean treatment difference -0.7; 95{\%} confidence interval [Ci]: -1.51, 0.10; p= 0.0842). The upper limit of the 95{\%} CI was less than the predefined threshold of 3 points for non-inferiority. Ropinirole 24-h prolonged release was well-tolerated when titrated more rapidly than ropinirole immediate release; overnight switching between formulations was also well-tolerated. Study limitations included complexity of the non-inferiority study design and the forced dose-titration schedule. Conclusion: Ropinirole 24-h prolonged release was effective and well-tolerated in patients with early Parkinson's disease.",
keywords = "Once-daily treatment, Parkinson's disease, Ropinirole",
author = "Fabrizio Stocchi and Hersh, {Bonnie P.} and Scott, {Burton L.} and Nausieda, {Paul A.} and Luigi Giorgi and P. Bourgeois and {De Deyn}, {P. P.} and R. Dom and A. Jeanjean and D. Roubcova and E. Ruzicka and M. Valis and A. Dest{\'e}e and R. Gil and F. Viallet and A. Csanyi and L. Csiba and P. Harcos and J. Czopf and A. Tak{\'a}cs and P. Barone and G. Nordera and M. Onofri and W. Drozdowski and H. Kwiecinski and W. Nyka and G. Opala and A. Szczudlik and B. Boothman and D. Burn and B. Castleton and D. Grosset and R. Weiser and C. Bernick and S. Cohen and A. Colcher and N. Leopold and L. Seeberger and N. Stoven",
year = "2008",
month = "10",
doi = "10.1185/03007990802387130",
language = "English",
volume = "24",
pages = "2883--2895",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease

T2 - A randomized, double-blind, non-inferiority crossover study

AU - Stocchi, Fabrizio

AU - Hersh, Bonnie P.

AU - Scott, Burton L.

AU - Nausieda, Paul A.

AU - Giorgi, Luigi

AU - Bourgeois, P.

AU - De Deyn, P. P.

AU - Dom, R.

AU - Jeanjean, A.

AU - Roubcova, D.

AU - Ruzicka, E.

AU - Valis, M.

AU - Destée, A.

AU - Gil, R.

AU - Viallet, F.

AU - Csanyi, A.

AU - Csiba, L.

AU - Harcos, P.

AU - Czopf, J.

AU - Takács, A.

AU - Barone, P.

AU - Nordera, G.

AU - Onofri, M.

AU - Drozdowski, W.

AU - Kwiecinski, H.

AU - Nyka, W.

AU - Opala, G.

AU - Szczudlik, A.

AU - Boothman, B.

AU - Burn, D.

AU - Castleton, B.

AU - Grosset, D.

AU - Weiser, R.

AU - Bernick, C.

AU - Cohen, S.

AU - Colcher, A.

AU - Leopold, N.

AU - Seeberger, L.

AU - Stoven, N.

PY - 2008/10

Y1 - 2008/10

N2 - Objective: This study compares once-daily ropinirole 24-h prolonged release and three-times-daily ropinirole immediate release in patients with early Parkinson's disease. Methods: This multicentre, double-blind, non-inferiority crossover study involved 161 patients randomized to one of four formulation sequences: (1) immediate release-immediate release-prolonged release; (2) immediate release-prolonged release-prolonged release; (3) prolonged release-prolonged release-immediate release; (4) prolonged release-immediate release-immediate release. During a 12-week dose-titration period, ropinirole immediate release was titrated according to the approved labelling; titration of ropinirole 24-h prolonged release started at a higher dose and was more rapid. Patients then entered three consecutive, flexible-dose, 8-week maintenance periods. At the end of the first maintenance period, half of the patients in each formulation group switched to the same or closest dose of the alternative formulation; remaining patients switched at the end of the second maintenance period. Results: At the end of titration, before the first dose switch, there were substantial reductions in mean Unified Parkinson's Disease Rating Scale (UPDRS) motor scores. During maintenance periods, both groups showed similar efficacy on the UPDRS motor score. Overall mean (standard error) change from period baseline was -0.1 (0.28) for ropinirole 24-h prolonged release, and 0.6 (0.30) for ropinirole immediate release (adjusted mean treatment difference -0.7; 95% confidence interval [Ci]: -1.51, 0.10; p= 0.0842). The upper limit of the 95% CI was less than the predefined threshold of 3 points for non-inferiority. Ropinirole 24-h prolonged release was well-tolerated when titrated more rapidly than ropinirole immediate release; overnight switching between formulations was also well-tolerated. Study limitations included complexity of the non-inferiority study design and the forced dose-titration schedule. Conclusion: Ropinirole 24-h prolonged release was effective and well-tolerated in patients with early Parkinson's disease.

AB - Objective: This study compares once-daily ropinirole 24-h prolonged release and three-times-daily ropinirole immediate release in patients with early Parkinson's disease. Methods: This multicentre, double-blind, non-inferiority crossover study involved 161 patients randomized to one of four formulation sequences: (1) immediate release-immediate release-prolonged release; (2) immediate release-prolonged release-prolonged release; (3) prolonged release-prolonged release-immediate release; (4) prolonged release-immediate release-immediate release. During a 12-week dose-titration period, ropinirole immediate release was titrated according to the approved labelling; titration of ropinirole 24-h prolonged release started at a higher dose and was more rapid. Patients then entered three consecutive, flexible-dose, 8-week maintenance periods. At the end of the first maintenance period, half of the patients in each formulation group switched to the same or closest dose of the alternative formulation; remaining patients switched at the end of the second maintenance period. Results: At the end of titration, before the first dose switch, there were substantial reductions in mean Unified Parkinson's Disease Rating Scale (UPDRS) motor scores. During maintenance periods, both groups showed similar efficacy on the UPDRS motor score. Overall mean (standard error) change from period baseline was -0.1 (0.28) for ropinirole 24-h prolonged release, and 0.6 (0.30) for ropinirole immediate release (adjusted mean treatment difference -0.7; 95% confidence interval [Ci]: -1.51, 0.10; p= 0.0842). The upper limit of the 95% CI was less than the predefined threshold of 3 points for non-inferiority. Ropinirole 24-h prolonged release was well-tolerated when titrated more rapidly than ropinirole immediate release; overnight switching between formulations was also well-tolerated. Study limitations included complexity of the non-inferiority study design and the forced dose-titration schedule. Conclusion: Ropinirole 24-h prolonged release was effective and well-tolerated in patients with early Parkinson's disease.

KW - Once-daily treatment

KW - Parkinson's disease

KW - Ropinirole

UR - http://www.scopus.com/inward/record.url?scp=55549147536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549147536&partnerID=8YFLogxK

U2 - 10.1185/03007990802387130

DO - 10.1185/03007990802387130

M3 - Article

C2 - 18768106

AN - SCOPUS:55549147536

VL - 24

SP - 2883

EP - 2895

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 10

ER -